Xellia pays steep price for factory delays

Novo company Xellia Pharmaceuticals has not generated the profits which it had hoped for and instead presents a notable deficit for 2020. The firm blames competitive prices and factory issues.
Photo: Xellia Pharmaceuticals / PR
Photo: Xellia Pharmaceuticals / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Following last year's record profit, Xellia Pharmaceuticals seemed to have started a new growth spurt, but this did not turn out to be the case. Danish media Børsen reports that instead, the firm reports a DKK 133m (USD 21.8m) deficit for 2020 compared to its DKK 400m profit in 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading